https://www.selleckchem.com/pr....oducts/crenolanib-cp
Iron overload cardiomyopathy is the most common cause of death in patients with transfusion-dependent thalassemia. The aim of this study was to determine the efficacy of carvedilol treatment in patients with transfusion-dependent thalassemia who had left ventricular diastolic dysfunction. Eighteen patients with transfusion-dependent thalassemia who had left ventricular diastolic dysfunction were enrolled. All patients had normal left ventricular systolic function and were given carvedilol with the target dose of 0.8 mg/kg/d
إعجاب
علق
شارك
